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DEPOSmONS of IgA in the renal glomerular mesan-
gial area are a hallmark of IgA nephropathy, and
are thought to be crucial for the onset of inflam-
mation processes in IgA nephropathy. In this
report we show that human mesangial cells (MC)
in vitro bind IgA and that binding of IgA
enhances the production of IL-6 by MC. Further-
more we show that the size of IgA is crucial in its
capability to enhance IL-6 production. Mono-
meric IgA does not affect basic IL-6 production,
whereas dimeric and polymeric IgA enhance IL-6
production up to 3- to 9-fold respectively. Addi-
tional studies demonstrate that enhanced IL-6
production by MC is not accompanied by
increased proliferation of human mesangial cells,
a f’mding which is distinct from that found with
rat mesangial cells. Taken together, these
fmdings suggest that deposition of dimeric and
polymeric IgA in the mesangial area of human
kidneys in IgA nephropathy may amplify local
inflammation.
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Introduction
Immunoglobulin A (IgA) is the predominant
immunoglobulin in human secretions and the
second most important immunoglobulin in the
circulation on a quantitative basis. 1’2 Depositions
of IgA in the glomerular mesangial area of the
kidney, as found in IgA nephropathy, are thought
to play a crucial role in the inflammatory pro-
cesses in this disease. The deposited IgA is
mainly of the IgA1 subclass and is thought to be
derived from the circulation.
4 Also co-depositions
of IgG and complement factors, such as comple-
ment component 3 (C3) are routinely seen in
renal biopsies of patients with IgA nephropathy.
5
Elevated serum levels of IgA,
6 increased produc-
tion of IgA1,
7 and a hyperresponse for IgA1 after
vaccination
7 is found in patients with IgA
nephropathy. The mechanisms of IgA deposition
in the kidney are still unclear. However, a
delayed clearance of IgA has been suggested.
Recently, a specific receptor for IgA was de-
scribed in rat and human renal glomerular
mesangial cells (CD89).9 It is not known whether
CD89 plays a role in IgA deposition in the kidney
during IgA nephropathy. It is interesting that
phagocytic blood cells of patients with IgA
nephropathy seem to be hampered in CD89-
mediated clearance of IgA.
10
Mesangial depositions of IgA have been asso-
ciated with increased levels of IL-6 in the urine of
patients with IgA nephropathy.
6 IL-6 is a potent,
(C) 1996 Rapid Science Publishers
multifunctional cytokine, which has multiple bio-
logical function activities on a wide variety of
tissues and cells, such as B- and T-lymphocytes,
myeloma cells, haematopoietic stem cells,
hepatocytes, fibroblasts
11 and rat glomerular
mesangial cells.
12 It was shown that IL-6 is pro-
duced by a variety of cells, such as macrophages,
lymphocytes, fibroblasts and endothelial cells.13-
17 Also, it has been shown that MC are able to
produce IL-6,18-2 which acts as an autocrine
growth factor for rat mesangial cells in vitro.2’2
In this study we demonstrate that human
MC bind IgA and produce IL-6 upon stimulation
with IgA in vitro. The degree of production of
IL-6 is dependent on the size of the IgA. Only
dimeric and polymeric IgA enhance IL-6 produc-
tion by MC. The IgA-induced production of IL-6
is inhibitable by cycloheximide, which indicates
de novo synthesis. Furthermore we show that
human MC do not proliferate upon stimulation
with IgA.
Materials and Methods
Cell culture: Glomerular mesengial cells (MC)
were cultured using glomeruli obtained from
human foetal kidneys of 12-19 weeks of gesta-
tion, by mechanical dissociation and sequential
22 23 sieving as described. Approval for the use of
foetal kidneys was obtained by informed consent
and from the medical ethics committee of the
hospital. After sieving, glomerular epithelial cells
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were removed by digestion with type 1A
collagenase (Sigma, St Louis, MO, USA) for 20
min at 37C. After washing, the resulting glom-
erular suspensions were resuspended in DMEM
(Seromed, Biochrom, Berlin, Germany) supple-
mented with 20% heat-inactivated foetal calf
serum (FCS) (Gibco, Breda, The Netherlands),
plated onto charged plastic culture Primaria
flasks (Falcon, Becton Dickinson, San Jose, CA)
and cultured at 37C in 5% CO2. After outgrowth
of the MC, the hillocks formed were lifted off the
culture flasks and explanted into 24-well culture
plates (Greiner, Alphen aan de Rijn, The Nether-
lands). MC growing out of the hillocks were sub-
cultured in T25 or T75 culture flasks (Greiner).
For the experiments MC were used between
subculture 2 and 8.
Isolation oflgA: Human IgA was isolated by chro-
matography using DEAE Sephadex (Pharmacia,
Uppsala, Sweden) anion exchange chromato-
graphy, and Sephacryl S-300 (Pharmacia) gel fil-
tration as described.
24 Purity of the final IgA
preparations was checked by SDS-poly-
acrylamide gel and ELISA for residual IgG and
IgM. The IgA preparations were shown to be free
of detectable IgG and IgM by ELISA.
Rat IgA was isolated as described,
25 briefly, IgA
containing ascites from Lewis rats, inoculated
intraperitoneally with 106 viable LO-DNP-45
hybridoma cells, was collected and precipitated
with a final concentration of 50% (NH4)2SO4,
The pellet was resuspended and dialysed against
phosphate-buffered saline (PBS)-2 mM EDTA
and IgA-anti-dinitrophenol (DNP) was affinity
purified using a DNP-lysine-coupled Sepharose
affinity column. After washing, anti-DNP-specific
IgA was eluted from the column with 0.1 M DNP.
After removal of free DNP by chromatography on
Dowex 1 (1 x 2 400), the IgA containing frac-
tions were pooled, concentrated and subjected
to gel filtration chromatography on a Sephacryl S-
300 column to yield monomeric, dimeric- and
polymeric IgA. The purified IgA preparations
were dialysed against PBS and were shown to be
devoid of detectable amounts of IgA and IgM, as
detected by ELISA.
Radiolabelling of IZ_: Human dimeric IgA was
radiolabelled with ">I using Iodo-Beads (Pierce,
Rockford, IL) according to the manufacturer’s
instructions. Non-incorporated iodine was separ-
ated from protein by gel filtration using Sepha-
dex G25 (Pharmacia). The specific activity was 3
l.tCi/l.tg protein.
Binding of IgA to MC: After growing to subcon-
fluency in 48-well plates, MC were washed three
times with PBS/0.5% bovine serum albumin
(BSA), and three wells were trypsinized to count
the number of cells present at the beginning of
the assay, using a Coulter Counter (Coulter Elec-
tronics, Mijdrecht, The Netherlands). Subse-
quently, MC were incubated for 16 h at 4C with
a dose response of iodinated human IgA in 300
btl DMEM/0.5%BSA in triplicate. After incubation,
the wells were washed three times with cold
PBS/0.5%BSA to remove non-bound radioactivity.
After washing, 300 l.tl 1 M NaOH was added per
well, to detach and solubilize the cells and sub-
sequently, the amount of radioactivity was meas-
ured and calculated per l.tg/105 cells. All data
were corrected for nonspecific binding.
IL-6production: Subconfluent 48-well plates with
MC were washed three times with phosphate
buffered saline (PBS) and cultured for an addi-
tional 48 h in DMEM/0.5%FCS to induce a quies-
cent state. After washing with DMEM/0.5%FCS,
fixed concentrations of IgA were added to the
cells in DMEM/0.5%FCS in triplicate. As a positive
control, MC were stimulated with 100 ng/ml LPS.
After 72 h of stimulation, supernatants were har-
vested and assessed for IL-6 production in the
B9-bioassay, using the I1-6-dependent murine
hybridoma cell line B9,20’26 kindly provided by
Dr L. A. Aarden (CLB, Amsterdam, The Nether-
lands) in combination with the Cell Titer 96
assay (Promega, Leiden, The Netherlands) to
measure proliferation. Serial dilutions of human
recombinant IL-6 were used as a standard.
Effect of cycloheximide on the production of IL-6
by MC: After growing MC to subconfluency in 48-
well plates, the cells were washed and incubated
further, either in medium alone, or in medium
containing 10 I.tg/ml human dimeric IgA, with or
without 1 lg/ml cyclohexamide in triplicate. After
72 h, the supernatants were harvested and used
in the B9 assay in serial dilutions of 1/20-1/640.
Cycloheximide at concentrations of less than 5
ng/ml does not interfere with the B9 assay. To
determine whether the cells remained viable
during incubation with cycloheximide, the cells
were washed with medium and incubated in
medium alone for another 72 h. After this second
incubation, the supernatants were harvested
again, and assessed for IL-6 using the B9 assay.
MC proliferation assay: MC, subconfluently
plated in 96- or 48-well plates, were washed
three times with phosphate buffered saline (PBS)
and cultured for an additional 48h in DMEM/
0.5% to induce a quiescent state. After washing
with DMEM/0.5%FCS, fixed amounts of the
various IgA preparations in DMEM/0.5%FCS were
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added in triplicate. As a positive control, 100 ng/
ml LPS was used. After 7 days of stimulation, the
cells were washed, trypsinized and counted by
using a Coulter Counter.
Results
To analyse the binding of IgA to MC, the MC
were incubated at 4C with a dose response of
25I-labelled human dimeric IgA for 16 h. Human
dimeric IgA was able to bind to MC in a dose-
dependent manner. Saturation was reached at
approximately 10 btg/ml (Fig. 1).
To investigate whether MC are activated
upon binding of IgA, MC were incubated at
37C in triplicate wells for 72 h in medium
(DMEM/10%FCS) alone, in medium supple-
mented with increasing concentrations of
human dimeric IgA, or in medium containing
100 ng/ml LPS, as a positive control. After stim-
ulation, the amount of IL-6 produced by the MC
was measured in the B9 assay. Basal production
of IL-6 by MC was 1 286 _+ 414 units IL-6 per
105 cells. Culture of MC with human dimeric
IgA resulted in up-regulation of IL-6 production
in a dose-dependent fashion. At the highest
concentration of 100 tg/ml, human dimeric IgA
was able to induce a 2.5-fold up-regulation of
3171 __+ 1400 units IL-6 per 105 cells (p <
0.05). LPS, as a positive control, induced a pro-
duction of 6043 +_ 2386 units IL-6 per 105
cells (Fig. 2).
To investigate whether the production of IL-6
is dependent on the size of IgA, MC were stimu-
lated in triplicate wells for 72 h with medium
alone, 0.1, 10 and 100 l.tg/ml rat monomeric,
dimeric, and polymeric IgA, or 100 ng/ml LPS.
Polymeric IgA was able to induce a three-fold
increase to 4 086 1443 units IL-6 per 105 cells
at a concentration of 10 l.tg/ml and a nine-fold
increase to 11800 __+ 300 units IL-6 per 105 cells
at a concentration of 100 l.tg/ml. Dimeric IgA
was much less potent in inducing an increase
of IL-6 production. At a concentration of
100 g/ml, dimeric IgA induced a production of
3 586 ___
1 471 units IL-6 per 105 cells, whereas
monomeric IgA did not induce a significant
increase in IL-6 production (Fig. 3).
To investigate whether the IL-6 produced by
the MC upon IgA stimulation is due to de novo
synthesis, MC were incubated in triplicate for
72 h in medium, or in medium supplemented
with 10 I.tg/ml human dimeric IgA, both with
or without cycloheximide (1 btg/ml), and
assessed for IL-6. Cycloheximide was able to
cause 97.3% inhibition of IgA-induced IL-6
release (p < 0.002) (Fig. 4).
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FIG. 2. Effect of increasing concentrations of human dimeric IgA
on the production of IL-6 by MC in vitro. MC were incubated in
triplicate with IgA for 72 h. After incubation the supernatants
were assessed for IL-6. The effect of LPS, as a positive control, is
also shown on the right.
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FIG. 1. Binding of 1251-1gA to MC following incubation of MC
with increasing concentrations of 1251-labelled human dimeric
IgA for 16 h at 4C. One of four representative experiments is
shown. Results are expressed as the mean -t- S.E.M. of triplicate
wells.
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FIG. 3. Effect of increasing concentrations of rat monomeric,
dimeric or polymeric IgA on the production of IL-6 by MC in
vitro. MC were incubated with various IgA preparations in tripli-
cate for 72 h. After incubation, the supernatants were harvested
and assessed for IL-6. One of three representative experiments is
shown. Results are expressed as the mean ___
S.E.M.
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FIG. 4. Effect of cycloheximide on the production of IL-6 by MC
/n v/tro. MC were incubated in triplicate with medium alone or
medium supplemented with human dimeric IgA (10 g/ml), with
or without cycloheximide (1 Ag/ml). Aer 72 h, the supernatants
were hawested and assessed for IL-6. Results are expressed as
the mean S.E.M.
It has been suggested that IgA is able to
induce proliferation of rat MC in vitro. To inves-
tigate whether human MC also proliferate upon
stimulation with IgA, MC were incubated in
medium alone (DMEM/0.5%FCS) or with various
preparations of IgA at a concentration of 10 l-tg/
ml. As a positive control 100 ng/ml LPS was
used. After 7 days of culture, the triplicate wells
were trypsinized and the total cell number per
well was determined by using the Coulter
Counter. None of the IgA preparations was able
to induce MC proliferation. In contrast, 100 ng/
ml LPS was able to induce a relative proliferation
of 2.24 4- 0.41 (p < 0.05) (Fig. 5).
Discussion
Glomerular mesangial depositions of IgA in the
kidney, together with IgG and complement com-
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FIG. 5. Effect of various preparations of IgA on the proliferation
of MC in vitro. MC were incubated with 10 lg/ml of various IgA
preparations and LPS, as a positive control. The relative prolifera-
tion is defined as the mean number of cells per well incubated
for 7 days with IgA or LPS, divided by the mean number of cells
per well incubated for 7 days with medium alone. Results are
expressed as the mean -i- SoE.M. of triplicate wells.
ponents such as C3, are thought to be crucial for
the onset of the inflammation process in IgA
nephropathy. It has been shown that IgG binds
tO MC27’28 and stimulates IL-6 production.18’2 In
this study, we show that human MC are capable
of secreting de novo synthesized IL-6 after stimu-
lation with IgA. The IL-6 production of the MC is
strongly dependent on the size of the IgA. Poly-
meric rat IgA is able to increase the IL-6 produc-
tion by MC up to nine-fold. Dimeric IgA is less
potent in increasing IL-6 production by MC and
only increased the basal production three-fold. In
contrast with polymeric and dimeric IgA, mono-
meric IgA is not able to increase the IL-6 produc-
tion.
It has been shown that IL-6 is an autocrine
growth factor for rat MC. 12’21 Even though
dimeric and polymeric IgA enhance the produc-
tion of IL-6 by human MC, we did not observe
proliferation of the cells. These findings are in
agreement with the observation that human MC
do not proliferate upon stimulation with IL-629’3
in vitro. In IL-6 transgenic mice, it was shown
that high plasma concentrations of IL-6 are asso-
ciated with mesangial proliferation. In humans,
however, it was found that urinary IL-6 levels do
not correlate with mesangial proliferative glomer-
ulonephritis.2 Our finding, that MC fail to pro-
liferate upon stimulation with IgA, is also in
accord with these findings. Therefore, our in
vitro data suggest that mesangial cell proliferation
in humans, as found in IgA nephropathy, is pre-
sumably not due to the autocrine effect of IL-6
produced by MC upon stimulation with IgA. The
precise mechanisms by which mesangial pro-
liferation is induced remain unclear, suggesting
that other mitogens, or combinations of different
mitogens acting synergistically, induce the mesan-
gial proliferation, as seen in IgA nephropathy.
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